戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 tions, including solar energy conversion and photochemotherapy.
2 ls in response to topical drug treatment and photochemotherapy.
3 intenance immunosuppression and prophylactic photochemotherapy.
4 th regard to the potential use of MKT-077 in photochemotherapy.
5 nt delivery of pyridine-containing drugs for photochemotherapy.
6 actinic keratosis, photodynamic therapy, and photochemotherapy.
7    The potential of both compounds to act as photochemotherapy agents was evaluated.
8 at require ligand photodissociation, such as photochemotherapy and photocatalysis, as well as for tho
9  to be useful for increasing the efficacy of photochemotherapy drugs by acting via two different mech
10                               Extracorporeal photochemotherapy (ECP) has been associated with clinica
11                               Extracorporeal photochemotherapy (ECP) has been shown to be an effectiv
12                               Extracorporeal photochemotherapy (ECP) is a safe, existing cellular the
13                               Extracorporeal photochemotherapy (ECP) is widely used to treat cutaneou
14 pical drugs and in mediating the response to photochemotherapy in psoriasis.
15                                              Photochemotherapy-in which a photosensitizing drug is co
16  as photoradiation therapy, phototherapy, or photochemotherapy, involves the use of a photoactive dye
17                      Psoralen and UVA (PUVA) photochemotherapy is associated with a dose-dependent in
18 ese findings, we conclude that IFN plus oral photochemotherapy is superior to IFN plus acitretin, ind
19 otosensitization processes and some forms of photochemotherapy, is nowadays becoming more and more im
20 erate disease; and systemic agents including photochemotherapy, oral agents, and newer injectable bio
21 ed ((3)MC) excited states are of interest in photochemotherapy (PCT) due to their potential to produc
22 ynamic therapy (PDT) and, more recently, for photochemotherapy (PCT).
23 after ingestion of the standard dose used in photochemotherapy (psoralen plus ultraviolet A).
24 n monotherapy, combinations of IFN with oral photochemotherapy (PUVA) or retinoids were investigated
25 s part of PUVA (psoralens and ultraviolet-A) photochemotherapy treatment for psoriasis.
26                                              Photochemotherapy was applied after oral intake of 8-met
27                                              Photochemotherapy with oral methoxsalen (psoralen) and u